Navigation Links
Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results from a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil) were presented at the American Transplant Congress. This and other Spare the Nephron (STN) trials in kidney and liver transplant recipients examine ways to prevent rejection without damaging kidneys.

As transplant patients are living longer, doctors are finding that older therapies such as steroids and calcineurin inhibitors (CNIs) can cause impairment of kidney function and damage to the blood vessels and filtering capacity of the kidneys.(1)(2) The STN trials are being conducted at more than 35 transplant centers in the United States and Canada and use CellCept and other immunosuppressants in combinations that reduce or eliminate the use of steroids and CNIs.

"Our goal for the Spare the Nephron trial in kidney transplant recipients is to determine the safest and most effective immunosuppressive therapy regimen that avoids the nephrotoxic effects of CNIs while preventing rejection," said Matthew Weir, M.D., professor and director of the division of nephrology at the University of Maryland School of Medicine. "The preliminary study results are very encouraging."

Dr. Weir reported that first-year results in kidney transplant recipients demonstrated that patients on CellCept and sirolimus maintenance therapy showed improvements in glomerular filtration rate (GFR) of their kidneys without increasing rejection rates.

A total of 208 of 305 kidney transplant patients completed 12 months of follow-up in this open-label, prospective, randomized, multicenter study. Patients initially treated with CellCept and a CNI were randomized to receive CellCept and sirolimus or to continue their current treatment regimen of CellCept and a CNI. Efficacy endpoints included the proportions of patients experiencing acute reject ion, graft loss, death, and the percent change in measured GFR.

After 12 months of follow-up, investigators found acute rejection in 6.1% of patients in the CellCept and sirolimus group, compared to 7.3% of patients in the CellCept and CNI group. Graft loss was experienced by 2.0% of patients in the CellCept and sirolimus group, compared to 3.6% of patients in the CellCept and CNI group.

None of the patients in the CellCept and sirolimus group died, while one patient death was remotely related to the CellCept and CNI group. Patients in the CellCept and sirolimus group had a median 18.5% increase from baseline in GFR, compared to a median 4.4% decrease in the CellCept and CNI group. Safety outcomes were similar in both groups.

Optimizing use of immunosuppressants for achieving long-term success is the primary focus of these clinical trials. Kidney STN, liver STN and OptiCept are all studying CellCept with the goal of reducing CNI associated nephrotoxicity therapy to prolong graft and patient survival. Final results of this study, which will be available later this year, will provide more definitive conclusions about the long-term effect of these regimens on renal function.

About CellCept

CellCept is an immunosuppressant or anti-rejection drug approved for use in combination with other immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients receiving kidney, heart and liver transplants.

There are no adequate and well-controlled studies in pregnant women. As CellCept has been shown to have teratogenic effects in animals at subclinical doses on a body surface area basis, it may cause fetal harm when administered to a pregnant woman. CellCept should not be used in pregnant women unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to beginning therapy even where there has been a history of infertility, unless due to hysterectomy.

Women of childbearing potential must use effective contraception before beginning CellCept therapy, during therapy and for six weeks following discontinuation of therapy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy occurs during treatment, the physician and patient should discuss the desirability of continuing the pregnancy (see complete product information).

Adverse events reported in >30% of renal, cardiac or liver transplant patients receiving CellCept (in combination with cyclosporine and corticosteroids) were pain, fever, headache, asthenia, anemia, leucopenia (patients should be monitored for neutropenia; dosing should be interrupted or the dose reduced if neutropenia develops), thrombocytopenia, leukocytosis, urinary tract infection, hypertension, hypotension, peripheral edema, hypercholesteremia, hypokalemia, hyperglycemia, creatinine, BUN and cough increased, hypomagnesemia, diarrhea, constipation, nausea, vomiting, respiratory infection, dyspnea, lung disorder, pleural effusion, tremor and insomnia.

Patients receiving immunosuppressant regimens are at increased risk of developing lymphomas and other malignancies, particularly of the skin.

Warning: Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: or

    All trademarks used or mentioned in this release are protected by law.

    (1) Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J

        Clin Pharmacol Ther 1996;34:515-9.

    (2) Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic

        cyclosporine nephropathy: the Achilles' heel of immunosuppressive

        therapy. Kidney Int 1996;50:1089-100.

CONTACT: Christopher Vancheri of Roche, +1-973-562-2203, or cell,+1-973-262-1175, , or Nichole Rothkopf ofKetchum, +1-646-935-3940, or cell, +1-646-942-0418,, for Roche

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Busin ess Media Company


Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
9. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
10. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
11. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer ... 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that on ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center ... with eating disorders as a result of the $20,000 raised at the center’s ... Fox Run Golf Club in Eureka, will help individuals who otherwise might not ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):